Raynaud's phenomenon (Q34299550)

1 August 2017

1 reference

title

Raynaud's phenomenon. (English)

1 reference

1 August 2017

J A Block

1

1 reference

1 August 2017

W Sequeira

series ordinal

2

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

357

1 reference

1 August 2017

issue

9273

1 reference

1 August 2017

page(s)

2042-2048

1 reference

Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon. The UK Scleroderma Study Group

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Different factors influencing the expression of Raynaud's phenomenon in men and women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Association between cigarette and alcohol consumption and Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Digital ulcers and necroses: novel manifestations of angiocentric lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Raynaud's phenomenon as a manifestation of parvovirus B19 infection: case reports and review of parvovirus B19 rheumatic and vasculitic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Helicobacter pylori eradication ameliorates primary Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Interferon-alpha induced Raynaud's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Severe Raynaud's phenomenon associated with interferon-beta treatment for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Vascular abnormalities in Raynaud's phenomenon.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Outcomes in primary Raynaud phenomenon: a meta-analysis of the frequency, rates, and predictors of transition to secondary diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Long-term outcome of Raynaud's syndrome in a prospectively analyzed patient cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Pathophysiology and classification of the vibration white finger

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Significance of anticentromere antibody in idiopathic Raynaud's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Anticentromere antibody--clinical associations. A study of 44 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Anti-collagen antibodies in systemic sclerosis and in primary Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

A novel anti-microfilament antibody, anti-135 kD, is associated with Raynaud's disease, undifferentiated connective tissue disease and systemic autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

An objective method to estimate the severity of Raynaud phenomenon: digital blood pressure response to cooling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Local cold exposure test as therapy control in patients with Raynaud's phenomenon: comparison between laser Doppler fluxmetry and simultaneous red blood cell velocity measurements in nailfold capillaries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Nerve conduction velocity study of the upper limb in Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Raynaud's phenomenon and vascular disease in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

1 reference

7 January 2021

The aetiology of Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Digital vascular responses and serum endothelin-1 concentrations in primary and secondary Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Functional studies in small arteries do not support a primary role for endothelin in the pathogenesis of Raynaud's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

OralL-arginine supplementation and cutaneous vascular responses in patients with primary Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Image analysis quantification of peptide-immunoreactive nerves in the skin of patients with Raynaud's phenomenon and systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Blockade of Vasospastic Attacks by α 2 -Adrenergic but Not α 1 -Adrenergic Antagonists in Idiopathic Raynaud’s Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

FACTOR VIII VON WILLEBRAND FACTOR ANTIGEN LEVELS CORRELATE WITH SYMPTOM SEVERITY IN PATIENTS WITH RAYNAUD'S PHENOMENON

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

White blood cell activation in Raynaud's phenomenon of systemic sclerosis and vibration induced white finger syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Assessment of platelet function in patients with Raynaud's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Plasma free and intraplatelet serotonin in patients with Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Thromboxane does not play a significant role in acute, cold-induced vasoconstriction in Raynaud's phenomenon. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Plasma levels of 5-hydroxytryptamine during sympathetic stimulation and in Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Familial aggregation of primary Raynaud's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

The menstrual cycle and Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Short-term estrogen administration improves abnormal endothelial function in women with systemic sclerosis and Raynaud's phenomenon.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Lack of habituation of the pattern of cardiovascular response evoked by sound in subjects with primary Raynaud's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Seasonal variations in cyclic GMP response on whole-body cooling in women with primary Raynaud's phenomenon.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Pharmacotherapy of Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Serotonin reuptake inhibitors in Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

The use of digital artery sympathectomy as a salvage procedure for severe ischemia of Raynaud's disease and phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Limited microsurgical arteriolysis for complications of digital vasospasm

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Treatment of primary Raynaud's syndrome with traditional Chinese acupuncture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905118-7

7 January 2021

10.1016/S0140-6736(00)05118-7

Identifiers

DOI

1 reference

1 August 2017

1 reference